Furthermore, IL-23 inhibitors appear effective and safe in special populations, including patients with concurrent inflammatory bowel disease, obesity, or advanced age (Blauvelt et al., 2023). This evidence concerns the gene IL37 and obesity due to melanocortin 4 receptor deficiency.